Drug Profile
AK 3280
Alternative Names: AK-3280T; AK3280; GDC 3280; RG 6069Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Ark Biosciences; Genentech
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Preclinical Hepatic fibrosis; Interstitial lung diseases
Most Recent Events
- 10 May 2023 Phase-I development in Idiopathic-pulmonary-fibrosis is ongoing (Ark Biosciences pipeline, May 2023)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Sweden (PO, Tablet)
- 14 Sep 2022 Phase-II clinical trials in Idiopathic pulmonary fibrosis (In adults, In the elderly) in China (PO) (Ark Biosciences pipeline, September 2022) (NCT05424887)